Treatment of primary central nervous system lymphoma in the immunocompetent patient;Traitement des lymphomes primitifs du système nerveux central chez l'immunocompétent

Revue Neurologique

Volumn 164, Issue 6-7, 2008, Pages 569-574

  Sierra Del Rio, M ^a   Benouaich Amiel, A ^a   Psimaras, D ^a   Dehais, C ^a   Hoang Xuan, K ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Central nervous system; Chemotherapy; Immunocompetent; Lymphoma; Methotrexate; Neurotoxicity; Radiotherapy; Steroids

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; VINCRISTINE;

BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG MEGADOSE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPETENCE; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOCOMPETENCE; LYMPHOMA; PROGNOSIS;

EID: 45949103287     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.04.001     Document Type: Review

References (45)

1. Abrey L.E., De Angelis L., and Yahalom J. Long term survival in primary central nervous system lymphoma. J Clin Oncol 16 (1998) 859-863
2. Abrey L.E., Moskowitz C.H., Mason W.P., Crump M., Stewart D., Forsyth P., et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21 (2003) 4151-4156
3. Abrey L.E., Yahalom J., and De Angelis L. Treatment of primary CNS lymphoma: the next step. J Clin Oncol 18 (2000) 3144-3150
4. Batchelor T., Carson K., O'Neill A., Grossman S.A., Alavi J., New P., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21 (2003) 1044-1049
5. Bessell E.M., Graus F., Lopez-Guillermo A., Lewis S.A., Villa S., Verger E., et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59 (2004) 501-508
6. Bessell E.M., Lopez-Guillermo A., Villa S., Verger E., Nomdedeu B., Petit J., et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 (2002) 231-236
7. Bessell E.M., Hoang-Xuan K., Ferreri A.J., and Reni M. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer 43 (2007) 1141-1152
8. Blay J.Y., Bouhour D., Carrie C., Bouffet E., Brunat-Mentigny M., Philip T., et al. The C5R protocol: A regimen of high dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 86 (1995) 2922-2929
9. Brada M., Hjiyiannakis D., Hines F., Traish D., and Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma. Int J Radiat Oncol Biol 40 (1998) 1157-1162
10. Camilleri-Broet S., Criniere E., Broet P., Delwail V., Mokhtari K., Moreau A., et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107 (2006) 190-196
11. Cheng T., Forsyth P., Chaudhry A., Morris D., Gluck S., Russell J.A., et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 (2003) 679-685
12. Cher L., Glass J., Harsh G.R., and Hochberg F.H. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46 (1997) 1757-1759
13. Colombat P., Lemevel A., Bertrand P., Delwail V., Rachieru P., Brion A., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38 (2006) 417-420
14. Dahlborg S.A., Henner W.D., Crossen J.R., Tableman M., Petrillo A., Braziel R., et al. Non AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2 (1996) 166-174
15. DeAngelis L.M., Seiferheld W., Schold S.C., Fisher B., Schultz C.J., and Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 (2002) 4643-4648
16. De Angelis L.M., Yahalom J., Thaler H.T., and Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10 (1992) 635-643
17. Freilich R.J., Monjour A., Delattre J.Y., and De Angelis L. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46 (1996) 435-440
18. Gabbai A., Hochberg F.H., Lindgood R.M., Bashir R., and Hotleman K. High dose methotrexate for non AIDS primary CNS lymphoma. J Neurosurg 70 (1989) 190-194
19. Glass J., Gruber M.L., Cher L., and Hochberg F.H. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long term outcome. J Neurosurg 81 (1994) 188-195
20. Glass J., Shustik C., Hochberg F.H., Cher L., and Gruber M.L. Therapy of primary central nervous system lymphoma with preirradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 30 (1996) 257-265
21. Guha-Thakurta N., Damek D., Pollack C., and Hochberg F. Intravenous methotrexate as initial treatment for primary central nervous system: response to therapy and quality of life patients. J Neurooncol 43 (1999) 259-268
22. Herrlinger U., Kuker W., Uhl M., Blaicher H.P., Karnath H.O., Kanz L., et al., Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57 (2005) 843-847
23. Hoang-Xuan K., Taillandier L., Chinot O., Frenay M., Hildebrand J., Monjour A., et al. Chemotherapy alone for primary central nervous system lymphoma in young patients. Neurology 50 Suppl. 4 (1998) A353
24. Hoang-Xuan K., Chinot O.L., and Taillandier L. Treatment of primary central nervous system lymphoma in the elderly. Semin Oncol 30 Suppl. 19 (2003) 53-57
25. Hoang-Xuan K., Taillandier L., Chinot O., Soubeyran P., Bogdhan U., Hildebrand J., et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21 (2003) 2726-2731
26. Hoang-Xuan K., Camilleri-Broet C., and Soussain G. Recent advance in primary central nervous system lymphoma. Curr Opin Oncol 16 (2004) 601-606
27. Illerhaus G., Marks R., Ihorst G., Guttenberger R., Ostertag C., Derigs G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 (2006) 3865-3870
28. Kadan-Lottick N.S., Skluzacek M.C., and Gurney J.G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95 (2002) 193-202
29. Louis E., Camilleri-Broët S, Hoang-Xuan K. (2005). lymphomes intracranienss. Encyclopédie médicochirurgicale, 20p.
30. McAllister L.D., Doolittle N.D., Guastadisegni P.E., Kraemer D.F., Lacy C.A., Crossen J.R., et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46 (2000) 51-60
31. Nelson D.F., Martz K., Bonner H., Nelson J.S., Newall J., Kerman H.D., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Rad Oncol Biol Phys 23 (1992) 9-17
32. Neuwelt E.A., Goldman D.L., Dahlborg S.A., Crossen J., Ramsey F., Roman-goldstein S., et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive functions. J Clin Oncol 9 (1991) 1580-1590
33. O'Brien P., Roos D., Pratt G., Liew K., Barton M., Poulsen M., et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18 (2000) 519-526
34. O'Neill B.P., O'Fallon J.R., Earle J.D., Colgan J.P., Brown L.D., and Krigel R.L. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy ?. Int J Radiat Oncol Biol Phys 33 (1995) 663-673
35. Omuro A.M., Ben-Porat L.S., Panageas K.S., Kim A.K., Correa D.D., Yahalom J., et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62 (2005) 1595-1600
36. Omuro A.M., Taillandier L., Chinot O., Carnin C., Barrie M., and Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85 (2007) 207-211
37. Pels H., Schmidt-Wolf I.G., Glasmacher A., Schulz H., Engert A., Diehl V., et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21 (2003) 4489-4495
38. Pirotte B., Levivier M., Goldman S., Brucher J.M., Brotchi J., and Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the litterature. J Neurooncol 32 (1997) 63-69
39. Poortmans P.M., Kluin-Nelemans H.C., Haaxma-Reiche H., Van't Veer M., Hansen M., Soubeyran P., Taphoorn M., et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 (2003) 4483-4488
40. Reni M., Ferreri A.J.M., Garancini M.P., and Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the litterature. Ann Oncol 8 (1997) 227-234
41. Sandor V., Stark-Vancs V., Pearson D., Nussenblat R., Whitcup S.M., Brouwers P., et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16 (1998) 3000-3006
42. Schultz C., Scott C., Sherman W., Donahue B., Fields J., Murray K., et al. Pre-irradiation chemotherapy with Cyclophosphamide, doxorubicin, vincristine, and Dexamethasone (CHOD) for PCNSL: Initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. J Clin Oncol 14 (1996) 556-564
43. Siobhan Ng, Rosenthal M.A., Ashley D., and Cher L. High dose methotrexate for primary CNS lymphoma in the elderly. Neurooncology 2 (2000) 40-44
44. Soussain C., Suzan F., Hoang-Xuan K., Cassoux N., Levy V., Azar N., et al. Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or first relapse primary central nervous system lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749
45. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. ; Société française de greffe de moëlle osseuse-thérapie cellulaire. (2008). Intensive chemotherapy followed by hematopoietic stem cell rescue for refractory and recurrent primary central nervous system and intraocular lymphoma. Results of a prospective phase II multicenter study. J Clin Oncol.